Genprex stock price soars due to approval of Japanese and European patents

2026-02-24 12:04:20

Investing.com – Genprex Inc (NASDAQ:GNPX) stock surged 27% on Monday after the company announced that the Japan Patent Office and the European Patent Office approved patents for its REQORSA gene therapy combined with immunotherapy for cancer treatment.

The Japanese patent covers the application of REQORSA in combination with PD-L1 antibodies for cancer treatment, while the European patent pertains to REQORSA combined with PD-1 antibodies for cancer therapy. These patents provide protection for the treatment combinations, including the company’s ongoing Phase 3 clinical trial, Acclaim-3, which uses REQORSA in combination with Genentech’s Tecentriq.

Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex, said, “The recent decisions by the Japan Patent Office and the European Patent Office to grant us patents for REQORSA in combination with immunotherapy further validate our innovative approach to cancer treatment.”

The company has obtained authorized patents in the U.S. and South Korea for the combination of REQORSA and PD-L1 antibodies, with patent applications in Australia currently under review. Genprex also holds patents for REQORSA combined with PD-1 antibodies in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore, and Europe.

Acclaim-3 is a Phase 1/2 clinical trial evaluating REQORSA and Tecentriq as maintenance therapy for extensive-stage small cell lung cancer patients who have responded to initial treatment with Tecentriq and chemotherapy. The Phase 2 expansion is expected to enroll approximately 50 patients, with the primary endpoint being the 18-week progression-free survival rate.

Genprex expects to complete enrollment of the first 25 patients for interim analysis in the first half of 2026, with the interim analysis anticipated in the second half of 2026. The trial has received FDA Fast Track and Orphan Drug designations.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.